Table 1.
Baseline characteristics of participants in the intervention group (Proxian®) and controls.
| Total (n = 32) | Intervention (n = 16) | Placebo (n = 16) | p | |
|---|---|---|---|---|
| Age, Mean ± SD ^ (range) * | 79.7 ± 10.3 (min 66; max 97) |
80.0 ± 10.2 (min 67; max 93) |
79.3 ± 10.0 (min 66; max 97) |
0.853 |
| Gender, n (%) ** | F 24 (75%), M 8 (25%) |
F 13 (81%), M 3 (19%) |
F 11 (69%), M 5 (31%) |
0.343 |
| Living, n (%) ** | Home 13 (41)%, NH 19 (59)% |
Home 6 (38%), NH 10 (62%) |
Home 7 (44%), NH 9 (56%) |
0.500 |
| Dementia, n (%) ** | 19 (59%) | 11 (69%) | 8 (50%) | 0.236 |
| Comorbidity, n (%) ** | 21 (66%) | 12 (75%) | 9 (56%) | 0.229 |
| BMI ^^, Mean ± SD ^ * | 19.6 ± 5.1 | 19.5 ± 5.4 | 19.7 ± 5.2 | 0.898 |
| Pressure ulcers, n (%) ** | 5 (16%) | 4 (25%) | 1 (6%) | 0.166 |
| Polypharmacy, n (%) ** | 21 (67%) | 9 (57%) | 12 (78%) | 0.694 |
| CRP ^^^ ≥ 0.8 mg/L, n (%) ** | 17 (53%) | 9 (56%) | 8 (50%) | 0.500 |
* Student’s t test; ** Fisher’s exact test for comparison of intervention to control group. ^ Standard deviation; ^^ Body Mass Index; ^^^ C- reactive protein.